Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB)
Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, add...
Saved in:
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/155760 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-155760 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1557602023-02-28T17:10:04Z Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) Lee, Bei Shi Pethe, Kevin School of Biological Sciences Lee Kong Chian School of Medicine (LKCMedicine) Science::Biological sciences::Biochemistry Cytochrome bcc:aa3 Mycobacterium Tuberculosis Oxidative Phosphorylation Q203 Respiration Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, additional novel antibiotics are needed for the treatment of multidrug-resistant tuberculosis (MDR-TB). Telacebec is a first-in-class antibiotic that targets the pathogen’s energy metabolism. Areas covered: This paper provides an overview of the recent progress in the development and testing of telacebec. We discuss published clinical data and examine the design and setup of its clinical trials. We also offer insights on the therapeutic potential of telacebec and aspects of which should be evaluated in the future. Expert opinion: The first phase 2a trial showed a correlation between dosage and bacterial load in patient sputum, which should be confirmed using a direct measurement method such as colonyforming unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development. Future clinical testing in combination with approved second-line drugs will reveal its full potential against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for Buruli ulcer and leprosy. National Research Foundation (NRF) Submitted/Accepted version This work was supported by the National Research Foundation (NRF) Singapore under its Investigatorship Program (grant NRF-NRFI06-2020- 0004) and NRF Competitive Research Programme (Project Award Number NRF-CRP18-2017-01). 2022-03-17T08:47:24Z 2022-03-17T08:47:24Z 2022 Journal Article Lee, B. S. & Pethe, K. (2022). Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB). Expert Opinion On Investigational Drugs, 31(2), 139-144. https://dx.doi.org/10.1080/13543784.2022.2030309 1354-3784 https://hdl.handle.net/10356/155760 10.1080/13543784.2022.2030309 2 31 139 144 en NRF-NRFI06-2020- 0004 NRF-CRP18-2017-01 Expert Opinion on Investigational Drugs © 2022 Informa UK Limited, trading as Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Investigational Drugs on 26 Jan 2022, available online: http://www.tandfonline.com/10.1080/13543784.2022.2030309. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Biological sciences::Biochemistry Cytochrome bcc:aa3 Mycobacterium Tuberculosis Oxidative Phosphorylation Q203 Respiration |
spellingShingle |
Science::Biological sciences::Biochemistry Cytochrome bcc:aa3 Mycobacterium Tuberculosis Oxidative Phosphorylation Q203 Respiration Lee, Bei Shi Pethe, Kevin Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
description |
Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed
6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance
threatens the global effort to eradicate this disease. With limited options available, additional novel
antibiotics are needed for the treatment of multidrug-resistant tuberculosis (MDR-TB). Telacebec is
a first-in-class antibiotic that targets the pathogen’s energy metabolism.
Areas covered: This paper provides an overview of the recent progress in the development and testing
of telacebec. We discuss published clinical data and examine the design and setup of its clinical trials.
We also offer insights on the therapeutic potential of telacebec and aspects of which should be
evaluated in the future.
Expert opinion: The first phase 2a trial showed a correlation between dosage and bacterial load in
patient sputum, which should be confirmed using a direct measurement method such as colonyforming
unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic
risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development.
Future clinical testing in combination with approved second-line drugs will reveal its full potential
against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for
Buruli ulcer and leprosy. |
author2 |
School of Biological Sciences |
author_facet |
School of Biological Sciences Lee, Bei Shi Pethe, Kevin |
format |
Article |
author |
Lee, Bei Shi Pethe, Kevin |
author_sort |
Lee, Bei Shi |
title |
Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
title_short |
Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
title_full |
Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
title_fullStr |
Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
title_full_unstemmed |
Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB) |
title_sort |
telacebec : an investigational antibacterial for the treatment of tuberculosis (tb) |
publishDate |
2022 |
url |
https://hdl.handle.net/10356/155760 |
_version_ |
1759855233174863872 |